UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
November 9, 2020
(Commission File No. 001-38475)
ASLAN PHARMACEUTICALS LIMITED
(REG. NO. 289175)
(Translation of registrant’s name into English)
CAYMAN ISLANDS
(Jurisdiction of incorporation or organisation)
83 CLEMENCEAU AVENUE
#12-03 UE SQUARE
SINGAPORE 239920
(Address of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):
Yes ☐ No ☒
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):
Yes ☐ No ☒
Announcement of third quarter 2020 financial results and corporate update
On November 9, 2020, ASLAN Pharmaceuticals Limited issued a press release announcing financial results for the third quarter ended 30 September 2020 and provided an update on its clinical activities.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Exhibits | ||
Exhibit |
| Exhibit Description |
|
| |
99.1 |
| Press release dated November 9, 2020 regarding 3Q20 financial release and corporate update. |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
|
|
ASLAN PHARMACEUTICALS LIMITED | |
(Registrant) | |
|
|
By: | /s/ Kiran Kumar Asarpota
|
Name: | Kiran Kumar Asarpota |
Title: | Chief Operating Officer |
Date: November 9, 2020